1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIDDK High Risk, High Impact Research is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the NIH. NIDDK supports high-risk, high-impact research to advance understanding and treatment of kidney diseases. Development of a bioartificial kidney would be considered high-impact research.
This would likely be pursued through general NIH funding mechanisms (e.
Get alerted about grants like this
Save a search for “National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the NIH” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Advancing Research & Health for All Enfermedad de los riñones Griffin P. Rodgers, M. D.
, M. A. C.
P. Heterogeneity of Diabetes Review recommendations from the NIDDK’s Working Group of Council on Heterogeneity of Diabetes. An updated article on infections associated with diabetes is available now.
Pathway to Kidney Recovery: Optimizing Outcomes in Acute Kidney Injury Requiring Dialysis Accelerating the Translation of Cell Therapy for Type 1 Diabetes Data Management & Sharing (DMS) Guidance, Tools and Resources NIDDK researchers can refer to NIDDK guidance for writing a DMS plan. NIDDK Labs Offer Research Training Opportunities Join our vibrant community at one of the most prestigious research institutions in the world.
Behavioral intervention decreases how much pain affects daily activities in people with dialysis-dependent kidney failure NIH study demonstrates long-term benefits of weight-loss surgery in young people Genomic variants that increase risk of kidney disease are found in nearly one-third of West Africans First wave of COVID-19 increased risk of heart attack, stroke up to three years later Work side-by-side with leading NIH scientists.
Where to register and what to do before you apply for a funding opportunity Research Training & Career Development NIDDK offers and participates in a variety of opportunities for researchers. Is Participating in Clinical Trials Right for You? Clinical trials offer hope for many people and an opportunity to help researchers find better treatments for others in the future.
Learn more about clinical trials Diabetes and Continuous Glucose Monitoring Talk to your doctor about continuous glucose monitoring to help manage your diabetes. Managing Chronic Kidney Disease Learn about the causes and complications of chronic kidney disease. Understanding Hepatitis D Discover the causes, symptoms, and treatment plan for Hepatitis D.
Based on current listing details, eligibility includes: Researchers at eligible institutions, generally including academic, non-profit, and for-profit organizations, with projects deemed high risk and high impact by NIH criteria. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs from NIDDK are competitive federal grant programs administered by the National Institute of Diabetes and Digestive and Kidney Diseases supporting innovative research by small businesses with potential for commercialization. NIDDK participates in both SBIR and STTR programs, with funding opportunities aligned to its mission areas in diabetes, digestive diseases, and kidney diseases. Eligible applicants are U.S. small businesses with innovative research applicable to NIDDK's scientific program areas. The NIH SEED website provides comprehensive application guidance and NIDDK-specific program contacts.
NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional) is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the NIH. This program encourages applications to plan multi-center clinical studies. While not specific to bioartificial kidneys, research planning for such complex medical devices would fall under clinical study implementation.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.